Sun Pharma share price fell over 3% to ₹1,738 apiece on NSE in Thursday’s trading session after the US Food and Drug Administration designated the company’s Baska manufacturing facility as Official Action Indicated (OAI).
(This is a developing story)
Disclaimer: This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.
